145 related articles for article (PubMed ID: 6766663)
21. [Blood and urinary values of CEA and CA 19-9 in patients with bladder carcinoma].
Cicigoi A; Rocca Rossetti S; Piantino P; Cerchier A
Minerva Med; 1986 Nov; 77(42-43):1983-7. PubMed ID: 3464851
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical demonstration of carcinoembryonic antigen (CEA) and its correlation with grading and staging on tissue sections of urinary bladder carcinomas.
Jautzke G; Altenaehr E
Cancer; 1982 Nov; 50(10):2052-6. PubMed ID: 6751517
[TBL] [Abstract][Full Text] [Related]
23. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder.
Feil G; Zumbrägel A; Päulgen-Nelde HJ; Hennenlotter J; Maurer S; Krause S; Bichler KH; Stenzl A
Anticancer Res; 2003; 23(2A):963-7. PubMed ID: 12820331
[TBL] [Abstract][Full Text] [Related]
24. Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder.
Farrow GM; Utz DC; Rife CC; Greene LF
Cancer Res; 1977 Aug; 37(8 Pt 2):2794-8. PubMed ID: 406039
[TBL] [Abstract][Full Text] [Related]
25. [Usefulness of carcinoembryonic antigen in transitional cell carcinoma of the bladder].
Moreno Sierra J; Ortega MD; Blanco Jimenez E; Maestro de las Casas ML; Delgado Marti JA; Hermida Gutierrez J; Salinas Casado J; Esteban Fuertes M; Resel Estévez L
Arch Esp Urol; 1994; 47(1):39-42. PubMed ID: 8192496
[TBL] [Abstract][Full Text] [Related]
26. [Usefulness of radiotherapy in the treatment of infiltrating bladder cancer].
Escudero Barrilero A
Arch Esp Urol; 1990; 43 Suppl 2():165-84. PubMed ID: 1710884
[No Abstract] [Full Text] [Related]
27. Clinical evaluation of urinary and serum carcinoembryonic antigen in bladder cancer.
Fraser RA; Ravry MJ; Segura JW; Go VL
J Urol; 1975 Aug; 114(2):226-9. PubMed ID: 1159914
[TBL] [Abstract][Full Text] [Related]
28. Urine carcinoembryonic antigen levels are more useful than serum levels for early detection of Bilharzial and non-Bilharzial urinary bladder carcinoma: observations of 43 Egyptian cases.
Saied GM; El-Metenawy WH; Elwan MS; Dessouki NR
World J Surg Oncol; 2007 Jan; 5():4. PubMed ID: 17224047
[TBL] [Abstract][Full Text] [Related]
29. Assessment of serial CEA determinations in urine of patients with bladder carcinoma.
Zimmerman R; Wahren B; Edsmyr F
Cancer; 1980 Oct; 46(8):1802-9. PubMed ID: 7427883
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of urine cytology and urine carcinoembryonic antigen (CEA) level in the distinction between bladder cancer and urinary tract infection.
Gajda M; Tyloch F; Jóźwicki W; Tyloch J; Sujkowska R; Skok Z
Int J Occup Med Environ Health; 1995; 8(2):103-8. PubMed ID: 7582848
[TBL] [Abstract][Full Text] [Related]
31. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Fisher HA
Prog Clin Biol Res; 1989; 310():275-83. PubMed ID: 2505271
[No Abstract] [Full Text] [Related]
32. Urinary CEA for prediction of survival time and recurrence in bladder cancer.
Wahren B; Nilsson B; Zimmerman R
Cancer; 1982 Jul; 50(1):139-45. PubMed ID: 7083117
[TBL] [Abstract][Full Text] [Related]
33. [Immunohistochemical demonstration of carcinoembryonic antigen (CEA) and ABO (H) blood group antigens on tissue sections of urinary bladder tumors].
Fujioka T; Tanji S; Koike H; Kubo T; Ohhori T
Hinyokika Kiyo; 1985 Oct; 31(10):1709-16. PubMed ID: 3911765
[TBL] [Abstract][Full Text] [Related]
34. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a double-monoclonal radioimmunoassay for the measurement of carcinoembryonic antigen in the urine of patients with bladder cancer.
Hetherington JW; Ewing R; Cooper EH
Eur Urol; 1986; 12(4):270-3. PubMed ID: 3743597
[TBL] [Abstract][Full Text] [Related]
36. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
37. [Comparative study of treatments of bladder carcinoma: TUR, thiotepa or BCG].
Rodrigues Netto Júnior N; Caserta Lemos G
Arch Esp Urol; 1981; 34(5):369-74. PubMed ID: 6800309
[No Abstract] [Full Text] [Related]
38. Carcinoembryonic antigen (CEA) in plasma of patients with carcinoma of the bladder/urethra.
Orjasaeter H; Fosså SD; Schjølseth SA; Fjaestad K
Cancer; 1978 Jul; 42(1):287-95. PubMed ID: 667800
[No Abstract] [Full Text] [Related]
39. [Urine examination for tumor cells using quantitative immunocytochemistry. Antibodies to a CEA-like antigen].
Sautner D; Saeger W
Fortschr Med; 1995 May; 113(14):207-9. PubMed ID: 7607589
[TBL] [Abstract][Full Text] [Related]
40. Plasma levels of CEA as a prognostic marker in carcinoma of urinary bladder.
Alsabti EA; Saffo MH
Urol Int; 1979; 34(5):387-92. PubMed ID: 494440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
